<DOC>
	<DOCNO>NCT00977509</DOCNO>
	<brief_summary>To compare frequency individual genetic abnormality tumor cell blood specimen .</brief_summary>
	<brief_title>Gene Mutations Non-Small Cell Lung Cancer Cells</brief_title>
	<detailed_description>Samples collect systemic therapy . After initiation therapy , sample collect end 1st month , end 2nd month end 3rd month every three month thereafter concurrently tumor assessment time perform CT scan . In select consented patient , peripheral blood sample collect every week first month . Disease status assess every 2~3 month end treatment accord RECIST criterion . If progression observe end therapy , patient assess every 3 month progression anti-cancer therapy . Progression-free survival , overall survival response rate report .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Pathologic cytological confirmation NSCLC . Patients must understand provide write informed consent prior initiation studyspecific procedure . Have life expectancy 3 month . Have malignant pleural/pericardial effusion metastatic nonsmall cell lung cancer . Have measurable evaluable disease . â‰¥20 year . Candidate systemic treatment EGFRTKI chemotherapy . Prior history another malignancy ( cure basal cell carcinoma skin cure insitu carcinoma cervix ) within 5 year study entry .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>gene</keyword>
	<keyword>mutation</keyword>
	<keyword>non-small cell lung cancer</keyword>
	<keyword>cancer cell</keyword>
</DOC>